title: Response to Carifi et al.'s letter.
authors.affiliation: 1 Department of Ophthalmology, Taipei Veterans General Hospital , Taipei, Taiwan .
authors.forename: Chang-Sue
authors.initials: CS
authors.lastname: Yang
authors.forename: Kuo-Che
authors.initials: KC
authors.lastname: Hung
authors.forename: Yi-Ming
authors.initials: YM
authors.lastname: Huang
authors.forename: Wen-Ming
authors.initials: WM
authors.lastname: Hsu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000628:therapy*; D005260:Female; D006801:Humans; D008028:Light Coagulation / Q000379:methods*; D008297:Male; D015861:Retinal Neovascularization / Q000628:therapy*; D014823:Vitreous Hemorrhage / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized